| Literature DB >> 12454641 |
Emanuel F Petricoin1, Joseph L Hackett, Lawrence J Lesko, Raj K Puri, Steven I Gutman, Konstantin Chumakov, Janet Woodcock, David W Feigal, Kathryn C Zoon, Frank D Sistare.
Abstract
The potential medical applications of microarrays have generated much excitement, and some skepticism, within the biomedical community. Some researchers have suggested that within the decade microarrays will be routinely used in the selection, assessment, and quality control of the best drugs for pharmaceutical development, as well as for disease diagnosis and for monitoring desired and adverse outcomes of therapeutic interventions. Realizing this potential will be a challenge for the whole scientific community, as breakthroughs that show great promise at the bench often fail to meet the requirements of clinicians and regulatory scientists. The development of a cooperative framework among regulators, product sponsors, and technology experts will be essential for realizing the revolutionary promise that microarrays hold for drug development, regulatory science, medical practice and public health.Mesh:
Year: 2002 PMID: 12454641 DOI: 10.1038/ng1029
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330